AMAG Pharmaceuticals — Q3 2017 Earnings Presentation
40 slides from AMAG Pharmaceuticals's earnings presentation, Nov 2, 2017
Slide 1: AMAG Pharmaceuticals Q3-2017 Financial Results & Corporate Update
AMAG Pharmaceuticals Q3-2017 Financial Results & Corporate Update November 2, 2017 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, beli
Slide 3: Q3-2017 Earnings Call Agenda
Q3-2017 Earnings Call Agenda Q3-2017 Highlights and Recent Events 1 5 Q&A 2 Product Portfolio Commercial Overview 4 Key Priorities and Closing Remarks 3 Financial Results and Guidance Update 3
Slide 4: Q3-2017 Highlights and Recent Events
Bill Heiden President & CEO Q3-2017 Highlights and Recent Events 4
Slide 5: AMAG's Expanding Portfolio of Products
AMAG’s Expanding Portfolio of Products Feraheme Treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) The only FDA-approved therapy to reduce recurrent preterm birth in certain at-risk women World’s largest umbilical cord stem cell collection and storage
Slide 6: Q3 Highlights and Recent Events
Q3 Highlights and Recent Events Intrarosa Launched the first and only FDA- approved locally administered non- estrogen product for dyspareunia on July 24 Phase 3 study initiated to assess the effectiveness of Intrarosa for HSDD (hypoactive sexual desire disorder) in post-menopausal women Bremela
Slide 7: Q3 Highlights and Recent Events Cont.
Q3 Highlights and Recent Events Cont. Feraheme Received FDA acceptance for review of Feraheme submission to broaden the current label to include the treatment of all adults with IDA with February 2, 2018 PDUFA date Feraheme abstracts selected for: – Nov. 3 podium presentation at ASN (Phase 3 hyp
Slide 8: Product Portfolio Commercial Overview
Product Portfolio Commercial Overview Nik Grund Chief Commercial Officer 8
Slide 9: Makena: Continued Growth
Makena: Continued Growth $93.4 $97.6 Q3-2016 Q3-2017 Makena Revenue ($M) M A T E R N A L H E A L T H : M A K E N A +5% 1 Company estimates Makena market share based on distributor dispensing data and all other market share based on physician market research data conducted by AMAG. 2 Based on 140,000
Slide 10: Makena: Increasing Underlying Demand
Inventory Weeks on Hand 2.6 2.9 2.4 est. 2.6 Makena: Increasing Underlying Demand1 M A T E R N A L H E A L T H : M A K E N A Makena Ex-factory Doses Makena Demand Doses 0 50 100 150 200 250 Q1-2017 Q2-2017 Q3-2017 Q4-2017 guidance (thousands) 1 Based on actual dispensing (shipments to physician/hosp
Slide 11: Makena Growth Drivers
M A T E R N A L H E A L T H : M A K E N A Makena Growth Drivers 1 If regulatory approval is received. Continue share gains from compounders and grow Makena @Home administration 2 Expand use in late preterm birth segment 3 Prepare for potential competitive threat in 2018 4 Prepare for Q1-2018 launch
Slide 12: CBR: Attractive Recurring Revenue Stream
CBR: Attractive Recurring Revenue Stream 12 Differentiate CBR’s offerings – Grew first time enrollments, the most profitable segment – Held first ever CBR Facebook live event 1 Build value proposition on storing newborn stem cells – Harmonizing annual storage price – Stabilized new enrollment pricin
Slide 13: Feraheme: Solid Financial Performance; Expected Future Growth
Solid Financial Performance; Expected Future Growth $22.3 $26.1 Q3-2016 Q3-2017 Feraheme Revenue1 ($M) 17% H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E 2017 Growth Drivers Continued growth in key segments Pull through recent GPO access wins Optimize net revenue per gram Prepare f
Slide 14: Feraheme label expansion doubles addressable IV iron market
4.5M Total U.S. Patients Diagnosed with Iron Deficiency Anemia4 Diagnosed IDA Patients Under the care of other physician specialists, including 1.5M in women’s health H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E 14 1 If regulatory approval is received for broader IDA indication. 2 AMAG
Slide 15: Intrarosa Update
Intrarosa Update 15
Slide 16: Intrarosa: Two Key Differentiators
16 Intrarosa: Two Key Differentiators W O M E N ’ S H E A L T H : I N T R A R O S A Non-Estrogen1 with No Boxed Warning Differentiated Mechanism of Action 1 Intrarosa is converted by enzymes in the body into androgens and estrogens, though the mechanism of action is not fully established. ® DHEA lev
Slide 17: Dyspareunia: Sizable Untapped Treatment Market
Affected, but not currently seeking treatment Utilizing OTC treatments Dyspareunia: Sizable Untapped Treatment Market Currently on Rx estrogen therapy Local (intra-vaginal) estrogen therapies = sales of >$1B per year2 1.7M women3 ~6M women3 ~12M women3 W O M E N ’ S H E A L T H : I N T R A R O S A ~
Slide 18: Intrarosa Early Launch Priorities
Intrarosa Early Launch Priorities 18 W O M E N ’ S H E A L T H : I N T R A R O S A 1. Create affordable access for patients Increase in percent of covered lives 2. Increase market awareness Number of first time prescribers 3. Increase HCP prescribing Market share Number of HCPs prescribing
Slide 19: Intrarosa Launched July 24, 2017
Intrarosa Launched July 24, 2017 19 Launched speakers program with >160 meetings scheduled in Q4-2017 Samples being distributed to HCP offices to facilitate new patient starts Broad and affordable patient access from launch – Comprehensive commercial copay savings program • $0 copay first mont
Slide 20: Launch Priority 1: Tracking to Year End Goal
62% 14% 24% 49% 23% 2% 26% Launch Priority 1: Tracking to 65% Year End Goal W O M E N ’ S H E A L T H : I N T R A R O S A 1 IMS FIA data, last 24 months, July 2017. 2 Market research sponsored by AMAG and conducted by Insight Strategy Advisors. 3 MMIT data as of 7/24/17, 9/30/17 and 10/31/17. 20 Com
Slide 21: Ensuring Success: Increase Market Awareness
Ensuring Success: Increase Market Awareness 70% 18% 4% 4% 4% OB/GYN Nurse Practitioner Physicians Asst. Family and Internal Medicine Other 21 W O M E N ’ S H E A L T H : I N T R A R O S A 1,963 Total HCPs Have Prescribed Intrarosa to date1 88% of Prescribing HCPs are OB/GYNs and NPs HCPs continue
Slide 22: Recent Intrarosa Events
• Attendance of ~700 (largest since conference began 20 years ago) • Maternal and women’s healthcare topics presented by nationally recognized speakers/experts Oct. 11-14, Seattle, WA NAMS 2017 Annual Meeting Planning Meeting October 6, 2017 Confidential - For Internal Use Only. Do Not Distribute. N
Slide 23: Ensuring Success: Increase HCP Prescribing
Ensuring Success: Increase HCP Prescribing W O M E N ’ S H E A L T H : I N T R A R O S A Vagifem/Yuva fem [VALUE] Estrace [VALUE] Premarin [VALUE] Estring [VALUE] Osphena [VALUE] Intrarosa [VALUE] Overall Market Share1 (Week ending 10/13/17) Product Market Share of Intrarosa Prescribers1 (Since 7/24
Slide 24: Performance vs. Previous Osphena Launch
Performance vs. Previous Osphena® Launch 24 W O M E N ’ S H E A L T H : I N T R A R O S A Aggregate TRx totals in first 13 weeks of launch – Intrarosa vs. Osphena1 TRx Intrarosa Osphena - 1,000 2,000 3,000 4,000 5,000 6,000 7,000 1 2 3 4 5 6 7 8 9 10 11 12 13 Week # 1 Based on IMS data for the first
Slide 25: Dyspareunia: Sizable Untapped Treatment Market
Affected, but not currently seeking treatment Utilizing OTC treatments Dyspareunia: Sizable Untapped Treatment Market Currently on Rx estrogen therapy Local (intra-vaginal) estrogen therapies = sales of >$1B per year2 1.7M women3 ~6M women3 ~12M women3 W O M E N ’ S H E A L T H : I N T R A R O S A ~
Slide 26: Intrarosa: In Summary
Only FDA-approved non-estrogen1 locally administered product for moderate to severe dyspareunia due to menopause – Only product without a boxed warning Differentiated mechanism of action Significant market opportunity with sizeable revenue potential Only 13 weeks into launch, significant pro
Slide 27: Financial Results and Guidance Update
Financial Results and Guidance Update Ted Myles Chief Financial Officer 27
Slide 28: Continued Product Revenue Growth and Portfolio Investments (GAAP)
$143.71 $153.7 ($249.7) $38.8 $380.21 $451.61 $64.3 ($286.1) Q3-2016 Q3-2017 Makena revenue CBR revenue Feraheme/MuGard revenue GAAP Operating income (loss) 7% YTD-2016 YTD-2017 19% 3-months Ended September 30 9-months Ended September 30 1 Excludes $40,000 in Q3-2016, $313,000 YTD-2016 and $53,000
Slide 29: Continued Product Revenue Growth and Portfolio Investments (Non-GAAP)
Continued Product Revenue Growth and Portfolio Investments $395.81 $188.3 $455.71 $164.4 YTD 2016 YTD 2017 15% $145.71 $76.2 $155.1 $56.7 Q3-2016 Q3-2017 6% 1 See slide 37 for a reconciliation of GAAP to non-GAAP financial results. 2 Excludes license fee, collaboration and other revenues of $40,00
Slide 30: Updated 2017 Financial Guidance
Updated 2017 Financial Guidance 30 ($M) 2017 GAAP Guidance 2017 Non-GAAP Guidance1 Previous Updated Previous Updated Makena sales $410 - $440 $385 - $395 $410 - $440 $385 - $395 Feraheme/MuGard sales $100 - $110 No change $100 - $110 No change CBR service revenue $110 - $120 No change $115 - $1252 N
Slide 31: Financial Results and Improved Balance Sheet Support Evolving Business Model
Longer term debt maturities that better align with business strategy Strong cash and investments balance of $394M and positive EBITDA generation support investments in: – Next generation products in current portfolio – Advancement of new product portfolio (Intrarosa and bremelanotide) – Expansio
Slide 32: Key Priorities & Closing Remarks
Key Priorities & Closing Remarks Bill Heiden President & CEO 32
Slide 33: AMAG Portfolio: Multiple Value Drivers
AMAG Portfolio: Multiple Value Drivers Milestone 2017 2018 2019 INTRAROSA Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Commercial launch in dyspareunia Initiate Phase 3 HSDD study Initiate digital consumer campaign MAKENA INTRAMUSCULAR FORMULATION Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Authorized generic readiness MAKENA S
Slide 34: Key Priorities
Key Priorities Intrarosa Drive successful launch ‒ Continue to increase the number of commercial covered lives ≥65% ‒ Expand number of prescribing physicians/nurses ‒ NRx and TRx (growth) Makena Increase patient market share and adherence to therapy Prepare for Q1-2018 launch of sub-q auto-inj
Slide 35: Q&A
amag AMAG Pharmaceuticals Q&A
Slide 36: Appendix
Appendix 36
Slide 37: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results ($M) GAAP operating income (loss) Purchase accounting adjustments related to CBR deferred revenue Depreciation and intangible asset amortization Non-cash inventory step-up adjustments Stock-based compensation Adjustments to contingent consideratio
Slide 38: Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance
Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance 2017 Financial Guidance ($M) GAAP net loss ($235) – ($220) Adjustments: Interest expense, net 68 Loss on debt extinguishment 10 Provision for income tax benefit (162) – (157) Operating income (loss) ($319) – ($299) Purchase accounting adjust
Slide 39: Share Count Reconciliation
Share Count Reconciliation 1 Employee equity incentive awards and convertible notes would be anti-dilutive in this period. 2 Reflects the Non-GAAP dilutive impact of employee equity incentive awards. 3 Reflects the impact of the non-GAAP benefit of the bond hedge and warrants. (M) Q3-2017 Q3-2016 YT
Slide 40: AMAG Pharmaceuticals Q3-2017 Financial Results & Corporate Update
AMAG Pharmaceuticals Q3-2017 Financial Results & Corporate Update November 2, 2017 40